Drug profile · INN
phenytoin sodium
DIPHENYLAN SODIUM
phenytoin sodium (DIPHENYLAN SODIUM) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — phenytoin sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
phenytoin sodium (DIPHENYLAN SODIUM) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is phenytoin sodium?
phenytoin sodium (DIPHENYLAN SODIUM) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for phenytoin sodium?
DIPHENYLAN SODIUM is a marketed brand name for phenytoin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of phenytoin sodium?
phenytoin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.